Literature DB >> 24072816

Approaches for assessing and discovering protein interactions in cancer.

Hisham Mohammed1, Jason S Carroll.   

Abstract

Significant insight into the function of proteins can be delineated by discovering and characterizing interacting proteins. There are numerous methods for the discovery of unknown associated protein networks, with purification of the bait (the protein of interest) followed by mass spectrometry as a common theme. In recent years, advances have permitted the purification of endogenous proteins and methods for scaling down starting material. As such, approaches for rapid, unbiased identification of protein interactomes are becoming a standard tool in the researchers toolbox, rather than a technique that is only available to specialists. This review will highlight some of the recent technical advances in proteomic-based discovery approaches, the pros and cons of various methods and some of the key findings in cancer-related systems. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072816      PMCID: PMC3834224          DOI: 10.1158/1541-7786.MCR-13-0454

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  Utility of formaldehyde cross-linking and mass spectrometry in the study of protein-protein interactions.

Authors:  Brent W Sutherland; Judy Toews; Juergen Kast
Journal:  J Mass Spectrom       Date:  2008-06       Impact factor: 1.982

2.  Streamlined analysis schema for high-throughput identification of endogenous protein complexes.

Authors:  Anna Malovannaya; Yehua Li; Yaroslava Bulynko; Sung Yun Jung; Yi Wang; Rainer B Lanz; Bert W O'Malley; Jun Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-22       Impact factor: 11.205

3.  Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.

Authors:  Jason S Carroll; X Shirley Liu; Alexander S Brodsky; Wei Li; Clifford A Meyer; Anna J Szary; Jerome Eeckhoute; Wenlin Shao; Eli V Hestermann; Timothy R Geistlinger; Edward A Fox; Pamela A Silver; Myles Brown
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

Review 4.  FOXA1 as a therapeutic target for breast cancer.

Authors:  Harikrishna Nakshatri; Sunil Badve
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

5.  Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer.

Authors:  Mingxing Ouyang; He Huang; Nathan C Shaner; Albert G Remacle; Sergey A Shiryaev; Alex Y Strongin; Roger Y Tsien; Yingxiao Wang
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

6.  FOXA1 is a key determinant of estrogen receptor function and endocrine response.

Authors:  Antoni Hurtado; Kelly A Holmes; Caryn S Ross-Innes; Dominic Schmidt; Jason S Carroll
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

7.  Stable-isotope labeling with amino acids in nematodes.

Authors:  Mark Larance; Aymeric P Bailly; Ehsan Pourkarimi; Ronald T Hay; Grant Buchanan; Sarah Coulthurst; Dimitris P Xirodimas; Anton Gartner; Angus I Lamond
Journal:  Nat Methods       Date:  2011-08-28       Impact factor: 28.547

8.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Authors:  Say Li Kong; Guoliang Li; Siang Lin Loh; Wing-Kin Sung; Edison T Liu
Journal:  Mol Syst Biol       Date:  2011-08-30       Impact factor: 11.429

9.  PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.

Authors:  Luca Magnani; Elizabeth B Ballantyne; Xiaoyang Zhang; Mathieu Lupien
Journal:  PLoS Genet       Date:  2011-11-17       Impact factor: 5.917

10.  Activation of rapid oestrogen signalling in aggressive human breast cancers.

Authors:  Coralie Poulard; Isabelle Treilleux; Emilie Lavergne; Katia Bouchekioua-Bouzaghou; Sophie Goddard-Léon; Sylvie Chabaud; Olivier Trédan; Laura Corbo; Muriel Le Romancer
Journal:  EMBO Mol Med       Date:  2012-10-15       Impact factor: 12.137

View more
  7 in total

1.  ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.

Authors:  Thomas M Campbell; Mauro A A Castro; Kelin Gonçalves de Oliveira; Bruce A J Ponder; Kerstin B Meyer
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

Review 2.  Visualizing the Architectures and Interactions of Nuclear Receptors.

Authors:  Sepideh Khorasanizadeh; Fraydoon Rastinejad
Journal:  Endocrinology       Date:  2016-10-05       Impact factor: 4.736

3.  A capture and release method based on noncovalent ligand cross-linking and facile filtration for purification of lectins and glycoproteins.

Authors:  Christina J Welch; Melanie L Talaga; Priyanka D Kadav; Jared L Edwards; Purnima Bandyopadhyay; Tarun K Dam
Journal:  J Biol Chem       Date:  2019-12-02       Impact factor: 5.157

4.  Structural Analysis of Hippocampal Kinase Signal Transduction.

Authors:  Daniel B McClatchy; Nam-Kyung Yu; Salvador Martínez-Bartolomé; Reesha Patel; Alexander R Pelletier; Mathieu Lavalle-Adam; Susan B Powell; Marisa Roberto; John R Yates
Journal:  ACS Chem Neurosci       Date:  2018-08-13       Impact factor: 4.418

5.  FOXM1 binds directly to non-consensus sequences in the human genome.

Authors:  Deborah A Sanders; Michael V Gormally; Giovanni Marsico; Dario Beraldi; David Tannahill; Shankar Balasubramanian
Journal:  Genome Biol       Date:  2015-06-23       Impact factor: 13.583

Review 6.  Application of metabolomics in drug resistant breast cancer research.

Authors:  Ayesha N Shajahan-Haq; Mehar S Cheema; Robert Clarke
Journal:  Metabolites       Date:  2015-02-16

7.  Listening to the Whispers in Neuroimmune Crosstalk: A Comprehensive Workflow to Investigate Neurotrophin Receptor p75NTR Under Endogenous, Low Abundance Conditions.

Authors:  Benjamin W Dorschner; Ralf Wiedemuth; Ann-Christin Funke; Marc Gentzel; Mary-Louise Rogers; Sebastian Brenner; Sebastian Thieme
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.